Dr. Reddy's to Release Q3 FY13 Results on February 14, 2013

Dr. Reddy's to Release Q3 FY13 Results on February 14, 2013

Earnings Call Slated for February 14, 6.30 PM IST / 8.00 AM EST*

HYDERABAD, India--(BUSINESS WIRE)-- Dr. Reddy's Laboratories (NYS: RDY) will announce results for the Third Quarter and Nine months ended December 31, 2012 on Thursday, February 14, 2013 after the Board Meeting. The results will be available on the Company's website www.drreddys.com.

Summary of Events

EventDate and Time (IST)Medium
Release of financial resultsFebruary 14th, after the Board Meeting

Email, Media, Company website, Business Wire

Earnings Call

February 14th, 6.30 PM IST / 8.00 AM EST

Hosted by the Company

(Details below)

Webcast of Earnings CallFebruary 14th, 6.30 PM IST / 8.00 AM EST through February 19th, 2013

URL available on Company's website,


Transcripts of the Earnings callWill be available on the Company's website

URL available on Company's website, www.drreddys.com


Earnings Call

Following the release, the management of the Company will host an earnings call to discuss the Company's financial performance.

Conference Dial-In Numbers
Primary Number: +91 22 3065 0136
Secondary Number: +91 22 6629 0356

The numbers listed above are universally accessible from all networks and all countries.

6000 1221

Available in - Ahmedabad, Bangalore, Chennai, Cochin, Delhi (NCR), Hyderabad, Kolkata, Lucknow

Local Access Number:

Accessible from all major carriers except BSNL/MTNL.

3940 3977

Available in Ahmedabad, Bangalore, Chandigarh, Chennai, Cochin, Gurgaon (NCR), Hyderabad, Kolkata, Lucknow, Pune


Accessible from all carriers.

USA: 1 866 746 2133

International Toll Free Number:

UK: 0 808 101 1573

Singapore: 800 101 2045


Hong Kong: 800 964 448


No password/pin number is necessary to dial in to any of the other calls. As participation in the call is limited, early registration is encouraged. The operator will provide instructions on asking questions before and during the call.

Audio Webcast

The audio webcast of the earnings call will be available to all interested parties at www.drreddys.com. Please visit the web site at least fifteen minutes ahead of the scheduled start time to register and to download and install any necessary audio software. Participants in the webcast can listen to the proceedings, but will not be able to ask questions. The replay will be available 2 hours after the earnings call, through Feb 19th, 2013. For play back dial in phone No: 022 3065 1212 and ID: 375#.


The transcript of the earnings call will also be available on the Company's website.

About Dr. Reddy's

Dr. Reddy's Laboratories Ltd. (NYS: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and pediatrics. Major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New Zealand. For more information, log on to: www.drreddys.com.

*EST- Eastern Standard Time

Dr. Reddy's Laboratories Ltd.
Investor Relations:
Kedar Upadhye, +91 40 66834297
Saunak Savla, +91 40 49002135
Milan Kalawadia (USA), +1 9082034931

KEYWORDS:   United States  Asia Pacific  North America  New York  India


The article Dr. Reddy's to Release Q3 FY13 Results on February 14, 2013 originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story